LabCorp Launches Neutralizing Antibody Test for COVID-19 Vaccine Development
The test results could potentially be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use.
LabCorp announced on June 25, 2020 that it launched a new test that can be used to assess the capacity of antibodies in patient plasma to inhibit the SARS-CoV-2 virus.
The test results could potentially be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use, according to a company press release. It will be available to biopharmaceutical companies, hospitals, blood banks, and other plasma-screening facilities.
“By leveraging our drug development and diagnostic capabilities, we are working tirelessly to find solutions to prevent and treat COVID-19,” said Paul Kirchgraber, MD, CEO, LabCorp’s Drug Development business. “The launch of this neutralizing antibody assay is the latest effort in our company’s commitment to accelerate the evaluation of vaccine candidates so that a successful candidate may reach patients sooner.”
Source: LabCorp
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
